Dolutegravir/rilpivirine

Drug Profile

Dolutegravir/rilpivirine

Alternative Names: DTG+RPV; Rilpivirine/dolutegravir

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Janssen Research & Development; ViiV Healthcare
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Nitriles; Oxazines; Pyrimidines; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III HIV infections

Most Recent Events

  • 22 Feb 2017 Pooled efficacy and safety data from the SWORD 1 and SWORD 2 phase III trials in HIV infections was released by ViiV Healthcare
  • 13 Feb 2017 ViiV Healthcare announces intention to submit regulatory applications for its two-drug regimen, dolutegravir/rilpivirine as a single tablet in 2017
  • 01 Oct 2016 ViiV Healthcare completes a phase I bioequivalence trial in healthy volunteers in USA (PO) (NCT02741557)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top